By Bill Hartzel, Director of Strategic Execution, Catalent and Andy Goll, Chief Operating Officer, Weiler Engineering, Inc.
As the industry continues its move toward biologics, innovative solutions and technologies will be needed to ensure a safe and reliable approach to the manufacturing and delivery of these drugs. One option is to leverage the advanced aseptic manufacturing of blow-fill-seal (B/F/S) technology, which has the potential to address the challenges of traditional glass filling as well as the global distribution of biologics.